Creo Medical Group (LON:CREO) Reaches New 12-Month Low – Time to Sell?

Creo Medical Group PLC (LON:CREO)’s share price reached a new 52-week low during trading on Friday. The stock traded as low as GBX 9.50 and last traded at GBX 9.67, with a volume of 2207440 shares. The stock had previously closed at GBX 9.80.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Trading Down 1.4%

The company has a debt-to-equity ratio of 8.09, a current ratio of 2.79 and a quick ratio of 2.19. The stock has a market cap of £46.96 million, a PE ratio of 9.67 and a beta of 1.56. The company’s fifty day moving average is GBX 12.62 and its 200-day moving average is GBX 12.82.

Creo Medical Group (LON:CREO) last issued its earnings results on Wednesday, September 30th. The company reported GBX (2) EPS for the quarter. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%. On average, analysts predict that Creo Medical Group PLC will post -10.0800005 earnings per share for the current fiscal year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.